|Day Low/High||13.98 / 15.09|
|52 Wk Low/High||11.30 / 67.90|
- Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on September 6, 2017 -
Industry veteran to help shape and execute value creation strategy across Merrimack's broad development pipeline
Key Appointments to Help Drive Merrimack's Refocused Research and Clinical Development Strategy
Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday.
Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.
Completes Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen
Presentations to include data on MM-310, a novel antibody-directed nanotherapeutic targeting EphA2, and istiratumab (MM-141), a monoclonal bispecific antibody that acts as a tetravalent inhibitor of IGF1-R and HER3
Investors in Merrimack Pharmaceuticals Inc. saw new options become available this week, for the May 19th expiration.
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
Investors in Merrimack Pharmaceuticals Inc. saw new options become available this week, for the April 21st expiration.
The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.
McKesson, Bristol-Myers and Varian were having a busy morning.
Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the September 15th expiration.
The Dow Jones Industrial Average's road to 20,000 has another detour as a selloff in crude spooks the energy sector.
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.
A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.
Stocks trade mostly lower Monday with the Dow Jones Industrial Average taking a pause in its race toward 20,000.
Merrimack Pharmaceuticals agreed to sell oncology treatments, including its pancreatic-cancer treatment Onivyde, to French drugmaker Ipsen.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.